Valuation: Celldex Therapeutics, Inc.

Market Cap 348.12Cr 301.68Cr 282.42Cr 257.69Cr 484.93Cr 33TCr 493.08Cr 3.31TCr 1.3TCr 17TCr 1.31TCr 1.28TCr 55TCr P/E 2026 *
-10.6x
P/E 2027 * -10.6x
Enterprise Value 281.89Cr 244.29Cr 228.69Cr 208.67Cr 392.67Cr 27TCr 399.27Cr 2.68TCr 1.05TCr 13TCr 1.06TCr 1.04TCr 45TCr EV / Sales 2026 *
1,418x
EV / Sales 2027 * 239x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celldex Therapeutics, Inc.

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 348.12Cr
-1.72%+0.68%+3.52%+14.37% 4.95TCr
-0.69%+6.25%+492.36%+585.40% 4.41TCr
+0.08%+11.23%+23.99%+81.74% 4.08TCr
+0.76%+6.85%+35.40%+10.92% 4.01TCr
+4.73%+13.29%+27.76%+54.22% 3.42TCr
+0.51%+5.29%+34.62%+126.87% 1.69TCr
-0.41%+4.08% - - 1.68TCr
-0.34%-0.03%+4.31%+20.81% 1.4TCr
+1.81%+20.45%+89.35%+31.49% 1.35TCr
Average +0.53%+7.75%+88.91%+115.73% 3TCr
Weighted average by Cap. +0.37%+7.39%+106.92%+138.24%

Financials

2026 *2027 *
Net sales 19.88L 17.23L 16.13L 14.72L 27.69L 19Cr 28.16L 1.89Cr 74.1L 9.49Cr 74.65L 73.02L 32Cr 1.19Cr 1.03Cr 96.71L 88.24L 1.66Cr 113.7Cr 1.69Cr 11Cr 4.44Cr 57Cr 4.48Cr 4.38Cr 189.87Cr
Net income -32Cr -27Cr -26Cr -23Cr -44Cr -3.02TCr -45Cr -301.7Cr -118.21Cr -1.51TCr -119.08Cr -116.49Cr -5.05TCr -36Cr -31Cr -29Cr -26Cr -49Cr -3.39TCr -50Cr -337.84Cr -132.37Cr -1.7TCr -133.35Cr -130.44Cr -5.66TCr
Net Debt -66Cr -57Cr -54Cr -49Cr -92Cr -6.32TCr -94Cr -630.04Cr -246.85Cr -3.16TCr -248.68Cr -243.26Cr -11TCr -64Cr -55Cr -52Cr -47Cr -89Cr -6.08TCr -90Cr -606.48Cr -237.62Cr -3.04TCr -239.38Cr -234.17Cr -10TCr
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
44.33USD
Average target price
58.07USD
Spread / Average Target
+30.99%

Quarterly revenue - Rate of surprise